PMID- 31415954
OWN - NLM
STAT- MEDLINE
DCOM- 20200923
LR  - 20200923
IS  - 1878-5905 (Electronic)
IS  - 0142-9612 (Linking)
VI  - 219
DP  - 2019 Oct
TI  - Advances in drug delivery for post-surgical cancer treatment.
PG  - 119182
LID - S0142-9612(19)30250-9 [pii]
LID - 10.1016/j.biomaterials.2019.04.027 [doi]
AB  - Surgery remains a primary modality of treatment for the majority of solid tumor 
      malignancies. While advancements in surgical technique and instrumentation have 
      improved the quality of life for cancer patients, local tumor recurrence and 
      metastasis after surgery remain challenging and result in a high rate of 
      mortality and decrease quality of life. It is therefore urgent to explore 
      effective methods to eliminate residual microscopic disease in the surgical site 
      and/or circulating tumor cells (CTCs) to inhibit tumor recurrence and minimize 
      the risk of distant metastasis. Recently, advances in bioengineering technology 
      have facilitated the development of drug delivery systems (DDSs) for the release 
      of chemotherapy and immunotherapy agents, which could be used to enhance the 
      effectiveness of surgical resection. In this review, we survey the rapidly 
      evolving fields of local and systemic controlled DDSs, utilizing a variety of 
      formulations and devices, such as implantable wafers, injectable/sprayable 
      hydrogels, micro/nanoparticles, and cellular particles. Opportunities and 
      challenges for the clinical translations of these delivery systems are also 
      discussed.
CI  - Copyright (c) 2019 Elsevier Ltd. All rights reserved.
FAU - Bu, Lin-Lin
AU  - Bu LL
AD  - Department of Bioengineering, University of California, Los Angeles, CA, 90095, 
      USA; Jonsson Comprehensive Cancer Center and Center for Minimally Invasive 
      Therapeutics, California NanoSystems Institute, University of California, Los 
      Angeles, CA, 90095, USA; The State Key Laboratory Breeding Base of Basic Science 
      of Stomatology (Hubei-MOST) & Key Laboratory of Oral Biomedicine Ministry of 
      Education, and Department of Oral Maxillofacial Head Neck Oncology, School and 
      Hospital of Stomatology, Wuhan University, Wuhan, Hubei, 430079, China.
FAU - Yan, Junjie
AU  - Yan J
AD  - Molecular Imaging Center, Key Laboratory of Nuclear Medicine, Ministry of Health, 
      Jiangsu Key Laboratory of Molecular Nuclear Medicine, Jiangsu Institute of 
      Nuclear Medicine, Wuxi, 214063, China.
FAU - Wang, Zejun
AU  - Wang Z
AD  - Department of Bioengineering, University of California, Los Angeles, CA, 90095, 
      USA; Jonsson Comprehensive Cancer Center and Center for Minimally Invasive 
      Therapeutics, California NanoSystems Institute, University of California, Los 
      Angeles, CA, 90095, USA.
FAU - Ruan, Huitong
AU  - Ruan H
AD  - Department of Bioengineering, University of California, Los Angeles, CA, 90095, 
      USA; Jonsson Comprehensive Cancer Center and Center for Minimally Invasive 
      Therapeutics, California NanoSystems Institute, University of California, Los 
      Angeles, CA, 90095, USA.
FAU - Chen, Qian
AU  - Chen Q
AD  - Department of Bioengineering, University of California, Los Angeles, CA, 90095, 
      USA; Jonsson Comprehensive Cancer Center and Center for Minimally Invasive 
      Therapeutics, California NanoSystems Institute, University of California, Los 
      Angeles, CA, 90095, USA.
FAU - Gunadhi, Vivienne
AU  - Gunadhi V
AD  - Department of Bioengineering, University of California, Los Angeles, CA, 90095, 
      USA; Jonsson Comprehensive Cancer Center and Center for Minimally Invasive 
      Therapeutics, California NanoSystems Institute, University of California, Los 
      Angeles, CA, 90095, USA.
FAU - Bell, R Bryan
AU  - Bell RB
AD  - Earle A. Chiles Research Institute at Robert W. Franz Cancer Center, Providence 
      Cancer Institute, Portland, OR, 97213, USA.
FAU - Gu, Zhen
AU  - Gu Z
AD  - Department of Bioengineering, University of California, Los Angeles, CA, 90095, 
      USA; Jonsson Comprehensive Cancer Center and Center for Minimally Invasive 
      Therapeutics, California NanoSystems Institute, University of California, Los 
      Angeles, CA, 90095, USA. Electronic address: guzhen@ucla.edu.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20190428
PL  - Netherlands
TA  - Biomaterials
JT  - Biomaterials
JID - 8100316
RN  - 0 (Hydrogels)
SB  - IM
MH  - Drug Delivery Systems/*trends
MH  - Humans
MH  - Hydrogels/chemistry
MH  - Immunotherapy
MH  - Nanotechnology
MH  - Neoplasms/*drug therapy/*surgery
OTO - NOTNLM
OT  - Cancer treatment
OT  - Drug delivery
OT  - Immunotherapy
OT  - Local delivery
OT  - Surgery
EDAT- 2019/08/16 06:00
MHDA- 2020/09/24 06:00
CRDT- 2019/08/16 06:00
PHST- 2019/03/13 00:00 [received]
PHST- 2019/04/23 00:00 [revised]
PHST- 2019/04/23 00:00 [accepted]
PHST- 2019/08/16 06:00 [pubmed]
PHST- 2020/09/24 06:00 [medline]
PHST- 2019/08/16 06:00 [entrez]
AID - S0142-9612(19)30250-9 [pii]
AID - 10.1016/j.biomaterials.2019.04.027 [doi]
PST - ppublish
SO  - Biomaterials. 2019 Oct;219:119182. doi: 10.1016/j.biomaterials.2019.04.027. Epub 
      2019 Apr 28.